Targeting cancer treatment using engineered extracellular vesicles to deliver microRNA
Developing extracellular vesicle-mediated targeted microRNA delivery system for EGFR cancers
This study is testing a new way to deliver special tiny molecules that can help fight cancer directly to cancer cells that have a specific marker, aiming to make treatment more effective and with fewer side effects for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Michigan State University NIH-funded |
| Lab location | 1 site (East Lansing, United States) |
| Project ID | NIH-10779474 on NIH RePORTER |
What this research studies
This research focuses on developing a new method to deliver therapeutic microRNAs specifically to cancer cells that express the Epidermal Growth Factor Receptor (EGFR). By using engineered extracellular vesicles, which are natural carriers in the body, the project aims to improve the delivery of these microRNAs while minimizing side effects and off-target impacts. The approach involves modifying the surface of these vesicles to enhance their targeting ability, allowing them to effectively reach and treat EGFR-positive cancer cells. The ultimate goal is to harness the anti-tumor properties of microRNAs to improve cancer treatment outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with cancers that express the Epidermal Growth Factor Receptor (EGFR).
Not a fit: Patients with cancers that do not express EGFR or those with other unrelated conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatments for patients with EGFR-positive cancers.
How similar studies have performed: Previous research has shown promise in using extracellular vesicles for targeted drug delivery, indicating potential success for this novel approach.
Where this research is happening
East Lansing, United States
- Michigan State University — East Lansing, United States (Active)
Researchers
- Principal investigator: Harada, Masako — Michigan State University
- Study coordinator: Harada, Masako
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.